Neurowyzr: Funding, Investors & Team (Sep 2026)
Neurowyzr offers the capability to identify, diagnose, treat, observe, and prevent cognitive decline in the brain.
Neurowyzr has raised $2.1M across 1 funding round on record, the most recent a Seed of $2.1M announced in Aug 2023.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Neurowyzr Company Profile and Key Stats
Latest funding round on record: Aug 2023.
Neurowyzr Funding Rounds
Neurowyzr Founders and Leadership Team
No contact details are on record for this team yet.
Neurowyzr Funding Compared to Other Health Care Startups
Neurowyzr's latest round of $2.1M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neurowyzr in Health Care and Bukit Merah
Companies Similar to Neurowyzr
Hello Health Group is creating a leading network of health technology platforms in developing markets,…
MaNaDr Mobile Health is a MedTech company founded by a team of doctors to harness the power of Information…
Elfie has the ambitious mission to save millions of lives every year. Our vision is to provide a holistic and…
ABM Respiratory Care is a medical technology startup creating ventilation products for those with pulmonary…
SynPhNe is a wearable device that combines brain and muscle training in one system. It assists individuals…
Adra is a software that helps dental clinics find cavities and other problems in x-rays faster and more…
Biorithm is a corporation that develops remote monitoring systems and point-of-care gadgets for pregnant and…
WhiteCoat, a digital healthcare provider, utilizes innovative and data-driven technology to provide on-demand…
Mobio Interactive has created and sold an AI-based digital theragnostic platform to meet the growing need for…
Quadria Capital is a private equity fund specializing in healthcare investments in rapidly developing…
Origin Health is a provider of AI-based fetal ultrasonography that helps clinicians perform pregnancy…
ThoughtFull aims to provide easy, affordable, and easily available mental healthcare services throughout…
Neurowyzr Funding FAQs
What does Neurowyzr do?
Neurowyzr offers the capability to identify, diagnose, treat, observe, and prevent cognitive decline in the brain.
How much funding has Neurowyzr raised?
Neurowyzr has raised $2.1M across 1 round on record. The most recent is a Seed of $2.1M announced in Aug 2023.
When did Neurowyzr last raise funding?
Neurowyzr's most recent funding round on record is a Seed of $2.1M, announced in Aug 2023.
Who is the CEO of Neurowyzr?
Sze Yunn Pang is listed as CEO at Neurowyzr.
Where is Neurowyzr headquartered?
Neurowyzr is based in Bukit Merah, Central Region, Singapore.
How many employees does Neurowyzr have?
Neurowyzr is in the 11-50 employee band.
How does Neurowyzr's funding compare to other Health Care startups?
Neurowyzr's latest round of $2.1M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Neurowyzr Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neurowyzr is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.